Survodutide vs Tirzepatide
How they differ
- FDA status. Survodutide: In clinical trials; not FDA-approved.1,2,3 Tirzepatide: FDA-approved as Mounjaro and Zepbound.4,5,6
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Survodutide | Tirzepatide |
|---|---|---|
| What it is | An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,7 | A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.4 |
| FDA status | In clinical trials In clinical trials; not FDA-approved1,2,3 Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.3 | FDA-approved FDA-approved as Mounjaro and Zepbound4,5,6 FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.4,5,6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.8 | Not among the six peptides the policy lists.8 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 13 ClinicalTrials.gov records and 4 PubMed records collected | 108 ClinicalTrials.gov records and 75 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 3FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 5Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026
- 8HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 10A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 11Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗
Nature Medicine · Official source · Source checked November 14, 2026
- 12ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 13Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 14Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026